Literature DB >> 9930867

Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection.

U Dittmer1, D M Brooks, K J Hasenkrug.   

Abstract

Infection by live attenuated retroviruses provides excellent protection from challenge with pathogenic viruses in several animal models, but little is known about which immune effectors are necessary for protection. We examined this using adoptive transfer experiments in the Friend virus mouse model. Transfers of immune spleen cells into naive mice conferred complete protection, and transfers of purified lymphocyte subsets demonstrated that this effect required complex immune responses involving CD4+ and CD8+ T cells and also B cells. In addition, passive immunization experiments demonstrated that antibodies alone reduced virus loads but did not prevent infection. These findings may have implications for retroviral vaccine design in general.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930867     DOI: 10.1038/5550

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  49 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.

Authors:  Anke R M Olbrich; Simone Schimmer; Klaus Heeg; Koen Schepers; Ton N M Schumacher; Ulf Dittmer
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Evolutionary dynamics of escape from biomedical intervention.

Authors:  Yoh Iwasa; Franziska Michor; Martin A Nowak
Journal:  Proc Biol Sci       Date:  2003-12-22       Impact factor: 5.349

4.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

5.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 9.  Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.

Authors:  Benjamin J Burwitz; Justin M Greene; David H O'Connor
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

10.  CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.

Authors:  Nora Manzke; Ilseyar Akhmetzyanova; Kim J Hasenkrug; Mirko Trilling; Gennadiy Zelinskyy; Ulf Dittmer
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.